TEMODAL AFTER SURGERY SIGNIFICANTLY IMPROVES SURVIVAL IN GBM PATIENTS

A A

Temodal capsules in combination with and following radiation therapy (RT) significantly improved median survival in patients with newly diagnosed glioblastoma multiforme (GBM) following resection of their tumor, according to data presented at the European Cancer Conference in Paris. An 18.3-month median survival was observed in patients who underwent complete resection followed by Temodal and RT compared with 14.2 months for those receiving RT alone after complete resection.

Treatment with Temodal/RT and followed by Temodal demonstrated an overall survival benefit compared to RT alone across all patient groups: those whose tumors were completely resected (18.3 months for patients receiving Temodal/RT vs. 14.2 months for those receiving RT alone); those whose tumors were partially resected (13.5 months for patients receiving Temodal/RT vs. 11.7 months for those receiving RT alone); or those whose tumors were biopsied.